EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanisms involved in cefiderocol resistance in French Pseudomonas aeruginosa clinical strains

Emma Gauthier, Matthieu Pisani, Maxime Bour, Mélanie Grosjean, Patrick Plésiat iD, Shahriar Safari, Ruben C Hartkoorn iD, Léa Souro, Emma Prétot iD, Katy Jeannot iD

Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)

DOI: 10.1128/aac.00520-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Emma Gauthier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Bactériologie, CNRS, Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CHU Besançon Franche-Comté, Besançon, France. Hauptthemen laut MEDLINE: Cephalosporins, Pseudomonas aeruginosa, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sante publique France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cefiderocol exhibits excellent in vitro activity against Pseudomonas aeruginosa ; however, resistance can emerge. We investigated the molecular mechanisms underlying cefiderocol resistance (minimal inhibitory concentration [MIC] >2 mg/L) in 103 clinical strains collected from 61 hospitals (2021–2024). MICs ranged from 4 to >128 mg/L, with 39.8% of strains showing MICs > 8 mg/L. Although 37.8% were classified as difficult-to-treat resistant (DTR), acquired β-lactamases were detected in 72.8% of strains, including carbapenemases (39.8%), mainly NDM-1 (29.1%), and extended-spectrum β-lactamases (ESBLs) (38.8%). Cloning of 11 β-lactamases into pUCP24, including the acquired cephalosporinase PAC-1 and ESBLs (VEB-1 and VEB-9), resulted in marked increases in cefiderocol MICs (up to 128-fold). Introduction of six mutations in the PDC enzyme into a PAO1Δ bla PDC-1 background increased MICs up to 4 mg/L and conferred cross-resistance to ceftolozane/tazobactam, notably T70I, F121L, G157D, and E219K. Alterations in siderophore transporters or regulators were identified in 38.8% of strains, most frequently a PirR frameshift (R132 fs ), consistent with PirR inactivation, which was confirmed in the PAO1 strain to contribute to cefiderocol resistance. Overall, cefiderocol resistance in clinical strains is multifactorial, mainly involving acquired β-lactamases (ESBLs and carbapenemases) and impaired siderophore uptake (PiuA/PiuD, PirA, and PiuC), leading to high-level resistance (>8 mg/L). The polyclonal distribution and diversity of mechanisms highlight the need for routine susceptibility testing and surveillance. Detection of NDM producers is critical, as cefiderocol should be used with caution in this context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CephalosporinsPseudomonas aeruginosaAnti-Bacterial AgentsCefiderocolMicrobial Sensitivity Testsbeta-LactamasesBacterial ProteinsHumansPseudomonas InfectionsFrance

Stichwörter der Autor:innen

Pseudomonas aeruginosaantimicrobial resistancecefiderocol

Substanzen

CefiderocolCephalosporinsAnti-Bacterial Agentsbeta-LactamasesBacterial Proteinscarbapenemase

Autor:innen und Institutionen

  • Laboratoire de Bactériologie, CNRS, Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CHU Besançon Franche-Comté, Besançon, France.
  • RD-Biotech Company, Besançon, France.
  • Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019-UMR 9017, Center for Infection and Immunity of Lille (CIIL), Lille, France.

ORCID-Profile: Patrick Plésiat, Ruben C Hartkoorn, Emma Prétot, Katy Jeannot

Förderung

  • Sante publique France

Zitieren

APA

Gauthier, E., Pisani, M., Bour, M., Grosjean, M., Plésiat, P., Safari, S., Hartkoorn, R. C., Souro, L., Prétot, E., & Jeannot, K. (2026). Mechanisms involved in cefiderocol resistance in French Pseudomonas aeruginosa clinical strains. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00520-26

Vancouver

Gauthier E, Pisani M, Bour M, Grosjean M, Plésiat P, Safari S, et al. Mechanisms involved in cefiderocol resistance in French Pseudomonas aeruginosa clinical strains. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00520-26

BibTeX
@article{Gauthier2026,
  author = {Gauthier, Emma and Pisani, Matthieu and Bour, Maxime and Grosjean, Mélanie and Plésiat, Patrick and Safari, Shahriar and Hartkoorn, Ruben C and Souro, Léa and Prétot, Emma and Jeannot, Katy},
  title = {Mechanisms involved in cefiderocol resistance in French Pseudomonas aeruginosa clinical strains},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {8},
  doi = {10.1128/aac.00520-26}
}
Kostenlos starten →